Aytu Biopharma (AYTU) Non-Current Assets (2011 - 2026)
Aytu Biopharma (AYTU) posted quarterly Non-Current Assets of $44.4 million for Q1 2026, down 14.17% year-over-year from $51.7 million in Q1 2025, and down 3.05% quarter-over-quarter from $45.8 million in Q4 2025.
Aytu Biopharma (AYTU) Non-Current Assets (2011 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Non-Current Assets for 16 consecutive years, with $44.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 14.17% year-over-year to $44.4 million; the TTM figure through Mar 2026 stood at $44.4 million (down 14.17% YoY), while the FY2025 annual figure was $45.0 million, down 19.94% from the prior year.
- Non-Current Assets eased to $44.4 million in Q1 2026 per AYTU's latest filing, from $45.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $90.9 million in Q1 2022 and bottomed at $43.9 million in Q3 2025.
- Historically, Non-Current Assets has averaged $60.2 million across 5 years, with a median of $57.7 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets sank 51.57% — and 2025, when it declined 10.47%.
- Aytu Biopharma's Non-Current Assets stood at $70.8 million in 2022, then slipped by 15.46% to $59.9 million in 2023, then slipped by 11.2% to $53.2 million in 2024, then fell by 13.94% to $45.8 million in 2025, then slipped by 3.05% to $44.4 million in 2026.
- Business Quant data shows AYTU's Non-Current Assets at $44.4 million in Q1 2026, $45.8 million in Q4 2025, and $43.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 2.96 Bn |
| 10 | Aytu Biopharma | 24.60 Mn | -2.12 Mn | 7.60 Mn | 44.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.36 Mn |
| Dec 31, 2025 | 45.76 Mn |
| Sep 30, 2025 | 43.88 Mn |
| Jun 30, 2025 | 45.00 Mn |
| Mar 31, 2025 | 51.69 Mn |
| Dec 31, 2024 | 53.17 Mn |
| Sep 30, 2024 | 55.09 Mn |
| Jun 30, 2024 | 56.20 Mn |
| Mar 31, 2024 | 57.73 Mn |
| Dec 31, 2023 | 59.88 Mn |
| Sep 30, 2023 | 62.29 Mn |
| Jun 30, 2023 | 65.38 Mn |
| Mar 31, 2023 | 68.75 Mn |
| Dec 31, 2022 | 70.83 Mn |
| Sep 30, 2022 | 75.59 Mn |
| Jun 30, 2022 | 77.69 Mn |
| Mar 31, 2022 | 90.88 Mn |
| Dec 31, 2021 | 136.28 Mn |
| Sep 30, 2021 | 138.69 Mn |
| Jun 30, 2021 | 160.43 Mn |